Article Text

Risperidone maintenance treatment increases time to symptom recurrence in young people with disruptive behaviour disorders

Statistics from

 Q Does long term risperidone maintenance improve symptoms in children and adolescents with disruptive behaviour disorders?


Embedded ImageDesign:

Randomised controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

Double blind.

Embedded ImageFollow up period:

Six months.

Embedded ImageSetting:

Twenty five centres in six European countries, Israel, and South Africa; 2001–03.

Embedded ImagePatients:

335 children and adolescents (aged 5–17 years) with conduct disorder, oppositional defiant disorder, or disruptive behaviour disorder not otherwise specified (DSM-IV and Schedule for Affective Disorders and Schizophrenia for School-Age Children - Present and Lifetime Version criteria) who responded to 12 weeks of risperidone (0.25 to 1.5 mg/day). Exclusions: moderate or severe intellectual impairment (IQ <55); Nisonger Child Behavior Rating Form - parent version (NCBRF) conduct problem subscale score <24; schizophrenia; bipolar disorder; other serious psychological or medical conditions; use of antispychotics, lithium, anticonvulsants, or antidepressants; or with no responsible caregiver.

Embedded ImageIntervention:

Participants were randomised to continuing risperidone treatment (0.25 to 1.5 mg/day) or placebo for six months.

Embedded ImageOutcomes:

Time to symptom recurrence (defined as a worsening of …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.